Aqua Pharmaceuticals Acquires US Rights to Veltin Gel and Altabax Ointment

Aqua Pharmaceuticals, LLC acquired the US rights to two dermatology products— Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% and Altabax (retapamulin) Ointment 1%, after Almirall, parent company of Aqua, acquired the rights to the products from GlaxoSmithKline. Both Veltin and Altabax will be promoted through Aqua in the United States.

Veltin is a prescription combination product containing clindamycin and tretinoin indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Altabax is a topical antibiotic indicated for the treatment of the skin infection impetigo due to susceptible strains of Staphylococcus aureus or Staphylococcus pyogenes in adults and pediatric patients 9 months of age or older.